Top

Published in:

01-02-2014 | AUTOIMMUNITY (TK TARRANT, SECTION EDITOR)

Targeting the Molecular and Cellular Interactions of the Bone Marrow Niche in Immunologic Disease

Authors: Jaime M. Brozowski, Matthew J. Billard, Teresa K. Tarrant

Published in: Current Allergy and Asthma Reports | Issue 2/2014

Abstract

Recent investigations have expanded our knowledge of the regulatory bone marrow (BM) niche, which is critical in maintaining and directing hematopoietic stem cell (HSC) self-renewal and differentiation. Osteoblasts, mesenchymal stem cells (MSCs), and CXCL12-abundant reticular (CAR) cells are niche components in close association with HSCs and have been more clearly defined in immune cell function and homeostasis. Importantly, cellular inhabitants of the BM niche signal through G protein-coupled surface receptors (GPCRs) for various appropriate immune functions. In this article, recent literature on BM niche inhabitants (HSCs, osteoblasts, MSCs, CAR cells) and their GPCR mechanistic interactions are reviewed for better understanding of the BM cells involved in immune development, immunologic disease, and current immune reconstitution therapies.

McCulloch EA, Till JE. The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice. Radiat Res. 1960;13:115–25.PubMed

Becker AJ, Mc CE, Till JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature. 1963;197:452–4.PubMed

Friedenstein AJ et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6(2):230–47.PubMed

McCulloch EA, Till JE. Proliferation of Hemopoietic Colony-Forming Cells Transplanted into Irradiated Mice. Radiat Res. 1964;22:383–97.PubMed

Till JE, Mc CE. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961;14:213–22.PubMed

Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol. 1976;47:327–59.PubMed

Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3(4):393–403.PubMed

Friedenstein AJ et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17(4):331–40.PubMed

Friedenstein AJ et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol. 1974;2(2):83–92.PubMed

10.

Friedenstein AJ et al. Origin of bone marrow stromal mechanocytes in radiochimeras and heterotopic transplants. Exp Hematol. 1978;6(5):440–4.PubMed

11.

Luria EA, Panasyuk AF, Friedenstein AY. Fibroblast colony formation from monolayer cultures of blood cells. Transfusion. 1971;11(6):345–9.PubMed

12.

Scadden DT. The stem-cell niche as an entity of action. Nature. 2006;441(7097):1075–9.PubMed

13.

Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells. 1978;4(1–2):7–25.PubMed

14.

Thomas ED. The Nobel Lectures in Immunology. The Nobel Prize for Physiology or Medicine, 1990. Bone marrow transplantation--past, present and future. Scand J Immunol. 1994;39(4):339–45.PubMed

15.

Gatti RA et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 1968;2(7583):1366–9.PubMed

16.

Griffith LM et al. Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases–a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy. Biol Blood Marrow Transplant. 2006;12(6):688–90.PubMed

17.

•• Gratwohl A et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica. 2013;98(8):1282–90. Extensive report on worldwide analysis of HCT and HSCT during a 3-year period: 2006–2008.PubMed

18.

Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330(12):827–38.PubMed

19.

Atkins HL et al. Autologous hematopoietic stem cell transplantation for autoimmune disease–is it now ready for prime time? Biol Blood Marrow Transplant. 2012;18(1 Suppl):S177–83.PubMed

20.

Gratwohl A et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617–24.PubMedCentralPubMed

21.

Petersdorf EW. The major histocompatibility complex: a model for understanding graft-versus-host disease. Blood. 2013;122(11):1863–72.PubMed

22.

Jansen J et al. Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med. 2005;9(1):37–50.PubMed

23.

Pavletic ZS et al. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol. 1997;15(4):1608–16.PubMed

24.

Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 2008;7(7):626–36.PubMed

25.

Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S48–56.PubMedCentralPubMed

26.

Milanetti F et al. Autologous hematopoietic stem cell transplantation for systemic sclerosis. Curr Stem Cell Res Ther. 2011;6(1):16–28.PubMed

27.

Naraghi K, van Laar JM. Update on stem cell transplantation for systemic sclerosis: recent trial results. Curr Rheumatol Rep. 2013;15(5):326.PubMed

28.

•• Frenette PS et al. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol. 2013;31:285–316. Vast review on defining MSCs and discussing their role in the BM niche, involvement in immune function, and therapeutic applications.PubMed

29.

Masuda S et al. Cotransplantation with MSCs improves engraftment of HSCs after autologous intra-bone marrow transplantation in nonhuman primates. Exp Hematol. 2009;37(10):1250–1257 e1.PubMed

30.

Cheshier SH, Prohaska SS, Weissman IL. The effect of bleeding on hematopoietic stem cell cycling and self-renewal. Stem Cells Dev. 2007;16(5):707–17.PubMed

31.

Baldridge MT, King KY, Goodell MA. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol. 2011;32(2):57–65.PubMedCentralPubMed

32.

Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2(6):640–53.PubMedCentralPubMed

33.

Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol. 2010;10(3):201–9.PubMed

34.

Wilson A et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118–29.PubMed

35.

Taichman RS, Reilly MJ, Emerson SG. Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood. 1996;87(2):518–24.PubMed

36.

Taichman RS, Emerson SG. Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J Exp Med. 1994;179(5):1677–82.PubMed

37.

Calvi LM et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841–6.PubMed

38.

Zhang J et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425(6960):836–41.PubMed

39.

Visnjic D et al. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood. 2004;103(9):3258–64.PubMed

40.

•• Doze VA, Perez DM. GPCRs in stem cell function. Prog Mol Biol Transl Sci. 2013;115:175–216. Thorough review on various G protein-coupled receptors and embryonic, induced pluripotent, cancer, and adult stem cells.PubMedCentralPubMed

41.

Sacchetti B et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131(2):324–36.PubMed

42.

Mendez-Ferrer S et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):829–34.PubMedCentralPubMed

43.

Rostovskaya M, Anastassiadis K. Differential expression of surface markers in mouse bone marrow mesenchymal stromal cell subpopulations with distinct lineage commitment. PLoS One. 2012;7(12):e51221.PubMedCentralPubMed

44.

Siegel G et al. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013;11:146.PubMedCentralPubMed

45.

Tokoyoda K et al. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity. 2004;20(6):707–18.PubMed

46.

Sugiyama T et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977–88.PubMed

47.

Sugiyama T, Nagasawa T. Bone marrow niches for hematopoietic stem cells and immune cells. Inflamm Allergy Drug Targets. 2012;11(3):201–6.PubMedCentralPubMed

48.

Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A. 1994;91(6):2305–9.PubMedCentralPubMed

49.

Nagasawa T et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382(6592):635–8.PubMed

50.

Nagasawa T. The chemokine CXCL12 and regulation of HSC and B lymphocyte development in the bone marrow niche. Adv Exp Med Biol. 2007;602:69–75.PubMed

51.

Kohara H et al. Development of plasmacytoid dendritic cells in bone marrow stromal cell niches requires CXCL12-CXCR4 chemokine signaling. Blood. 2007;110(13):4153–60.PubMed

52.

Noda M et al. CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice. Blood. 2011;117(2):451–8.PubMed

53.

Omatsu Y et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity. 2010;33(3):387–99.PubMed

54.

Zhu J et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood. 2007;109(9):3706–12.PubMed

55.

Kiel MJ et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121(7):1109–21.PubMed

56.

Pinho S et al. PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J Exp Med. 2013;210(7):1351–67.PubMedCentralPubMed

57.

• Ding L, Morrison SJ. Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 2013;495(7440):231–5. Demonstrates that different stem and progenitor cells occupy distinct BM niches—simultaneous study; see Greenbaum et al.PubMedCentralPubMed

58.

Hsu YC, Fuchs E. A family business: stem cell progeny join the niche to regulate homeostasis. Nat Rev Mol Cell Biol. 2012;13(2):103–14.PubMedCentralPubMed

59.

• Greenbaum A et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013;495(7440):227–30. Demonstrates different stem and progenitor cells occupy distinct BM niches— simultaneous study; see Ding et al.PubMedCentralPubMed

60.

Heazlewood SY et al. Megakaryocytes co-localise with hemopoietic stem cells and release cytokines that up-regulate stem cell proliferation. Stem Cell Res. 2013;11(2):782–92.PubMed

61.

Calvi LM, Link DC. Cellular Complexity of the Bone Marrow Hematopoietic Stem Cell Niche. Calcif Tissue Int. 2013.

62.

DeWire SM et al. Beta-arrestins and cell signaling. Annu Rev Physiol. 2007;69:483–510.PubMed

63.

Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys. 2008;473(2):218–24.PubMed

64.

Calvi LM. Osteoblastic activation in the hematopoietic stem cell niche. Ann N Y Acad Sci. 2006;1068:477–88.PubMed

65.

Smith JN, Calvi LM. Concise review: Current concepts in bone marrow microenvironmental regulation of hematopoietic stem and progenitor cells. Stem Cells. 2013;31(6):1044–50.PubMed

66.

Brunner S et al. Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells. Am J Physiol Endocrinol Metab. 2007;293(6):E1670–5.PubMed

67.

Calvi LM et al. Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells. Blood. 2012;119(11):2489–99.PubMed

68.

Chemokine/chemokine receptor nomenclature. Cytokine. 2003;21(1):48–9.

69.

Vila-Coro AJ et al. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. Faseb J. 1999;13(13):1699–710.PubMed

70.

Forster R et al. Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation. J Immunol. 1998;160(3):1522–31.PubMed

71.

Wynn RF et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood. 2004;104(9):2643–5.PubMed

72.

Sordi V et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood. 2005;106(2):419–27.PubMed

73.

Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol. 2006;34(8):967–75.PubMed

74.

Premont RT, Inglese J, Lefkowitz RJ. Protein kinases that phosphorylate activated G protein-coupled receptors. Faseb J. 1995;9(2):175–82.PubMed

75.

Balabanian K et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood. 2005;105(6):2449–57.PubMed

76.

Balabanian K et al. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest. 2008;118(3):1074–84.PubMedCentralPubMed

77.

Mueller W, et al. Hierarchical organization of multi-site phosphorylation at the CXCR4 C terminus. PLoS One. 8(5):e64975.

78.

Tarrant TK, et al. G protein-coupled receptor kinase-3-deficient mice exhibit WHIM syndrome features and attenuated inflammatory responses. J Leukoc Biol.

79.

Pappu R et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316(5822):295–8.PubMed

80.

Ito K et al. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun. 2007;357(1):212–7.PubMed

81.

Venkataraman K et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J. 2006;397(3):461–71.PubMed

82.

Hisano Y et al. Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells. PLoS One. 2012;7(6):e38941.PubMedCentralPubMed

83.

Fukuhara S et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest. 2012;122(4):1416–26.PubMedCentralPubMed

84.

Yatomi Y et al. Sphingosine 1-phosphate: synthesis and release. Prostaglandins. 2001;64(1–4):107–22.PubMed

85.

Bendall LJ, Basnett J. Role of sphingosine 1-phosphate in trafficking and mobilization of hematopoietic stem cells. Curr Opin Hematol. 2013;20(4):281–8.PubMed

86.

Billich A et al. Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis. PLoS One. 2013;8(3):e59630.PubMedCentralPubMed

87.

• Golan K, Kollet O, Lapidot T. Dynamic cross talk between S1P and CXCL12 regulates hamatopoietic stem cells migration, development, and bone remodeling. Pharmaceuticals. 2013;6(9):1145–69. Review that highlights the concept of synchronized S1P/S1PR and CXCL12/CXCR4 interactions in HSC mobilization.PubMed

88.

Kimura T et al. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells. Blood. 2004;103(12):4478–86.PubMed

89.

Meriane M et al. Cooperation of matrix metalloproteinases with the RhoA/Rho kinase and mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase signaling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells. Stem Cells. 2006;24(11):2557–65.PubMed

90.

Zhang L et al. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. J Exp Med. 2012;209(12):2165–81.PubMedCentralPubMed

91.

Maceyka M et al. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22(1):50–60.PubMedCentralPubMed

92.

Bagdanoff JT et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J Med Chem. 2010;53(24):8650–62.PubMed

93.

Bagdanoff JT et al. Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. J Med Chem. 2009;52(13):3941–53.PubMed

94.

Arnon TI et al. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science. 2011;333(6051):1898–903.PubMedCentralPubMed

95.

Ryu JM et al. Sphingosine-1-phosphate-induced Flk-1 transactivation stimulates mouse embryonic stem cell proliferation through S1P/S1P-dependent beta-arrestin/c-Src pathways. Stem Cell Res. 2013;12(1):69–85.PubMed

96.

Golan K et al. S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release. Blood. 2012;119(11):2478–88.PubMed

97.

Bonig H, Papayannopoulou T. Hematopoietic stem cell mobilization: updated conceptual renditions. Leukemia. 2013;27(1):24–31.PubMedCentralPubMed

98.

Motabi IH, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2012;26(6):267–78.PubMed

99.

Arcese W, De Angelis G, Cerretti R. Granulocyte-mobilized bone marrow. Curr Opin Hematol. 2012;19(6):448–53.PubMed

100.

Levesque JP et al. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001;98(5):1289–97.PubMed

101.

Levesque JP et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111(2):187–96.PubMedCentralPubMed

102.

Levesque JP et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood. 2004;104(1):65–72.PubMed

103.

Devine SM et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. J Clin Oncol. 2004;22(6):1095–102.PubMed

104.

DiPersio JF et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767–73.PubMed

105.

Maziarz RT et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biol Blood Marrow Transplant. 2013;19(4):670–5.PubMed

106.

Sison EA, Brown P. The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Rev Hematol. 2011;4(3):271–83.PubMedCentralPubMed

107.

Tavor S et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia. 2008;22(12):2151–5158.PubMed

108.

Kang Y et al. Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model. PLoS One. 2010;5(6):e11316.PubMedCentralPubMed

109.

Dale DC et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood. 2011;118(18):4963–6.PubMed

110.

Ballen KK et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007;13(7):838–43.PubMed

111.

Ballen K et al. Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012;18(12):1851–8.PubMedCentralPubMed

112.

Whetton AD et al. Lysophospholipids synergistically promote primitive hematopoietic cell chemotaxis via a mechanism involving Vav 1. Blood. 2003;102(8):2798–802.PubMed

113.

Massberg S et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell. 2007;131(5):994–1008.PubMedCentralPubMed

114.

Halin C et al. The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. Blood. 2005;106(4):1314–22.PubMed

115.

Maeda Y et al. Sphingosine 1-phosphate receptor type 1 regulates egress of mature T cells from mouse bone marrow. Int Immunol. 2010;22(6):515–25.PubMed

116.

Pereira JP, Xu Y, Cyster JG. A role for S1P and S1P1 in immature-B cell egress from mouse bone marrow. PLoS One. 2010;5(2):e9277.PubMedCentralPubMed

117.

Allende ML et al. Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. J Biol Chem. 2011;286(9):7348–58.PubMed

118.

Juarez JG et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood. 2012;119(3):707–16.PubMed

119.

McDermott DH, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood. 118(18):4957–62.

120.

Song JS, et al. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med. 42(6):465–72.

121.

Makino H, et al. Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in mice. J Med Invest. 60(1–2):127–37.

122.

Yannaki E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 20(1):230–8.

123.

Pulliam AC et al. AMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi anemia knockout mice. Exp Hematol. 2008;36(9):1084–90.PubMed

124.

Nishimura Y, et al. CXCR4 antagonist AMD3100 accelerates impaired wound healing in diabetic mice. J Invest Dermatol. 132(3 Pt 1):711–20.

125.

MacFarland R, et al. A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol Blood Marrow Transplant. 16(1):95–101.

126.

Uy GL, et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. 119(17):3917–24.

127.

DiPersio JF et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–6.PubMed

128.

Cashen A et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1253–61.PubMed

129.

Hubel K, et al. European data on stem cell mobilization with plerixafor in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant. 47(8):1046–50.

130.

Attolico I, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant. 18(2):241–9.

131.

Rubin JB et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A. 2003;100(23):13513–8.PubMedCentralPubMed

132.

Redjal N et al. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res. 2006;12(22):6765–71.PubMed

133.

Vives S, et al. Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing’s sarcoma. J Clin Apher. 27(5):260–2.

134.

Devine SM et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112(4):990–8.PubMed

135.

Shepherd RM et al. Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100. Blood. 2006;108(12):3662–7.PubMed

136.

Kappos L et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124–40.PubMed

137.

Kappos L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 362(5):387–401.

138.

Comi G, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler. 16(2):197–207.

139.

O’Connor P et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009;72(1):73–9.PubMed

140.

Kurose S et al. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp Eye Res. 2000;70(1):7–15.PubMed

141.

Commodaro AG, et al. Evaluation of experimental autoimmune uveitis in mice treated with FTY720. Invest Ophthalmol Vis Sci. 51(5):2568–74.

142.

Copland DA, et al. Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier. Am J Pathol. 180(2):672–81.

143.

Zhang Z et al. Distribution of Foxp3(+) T-regulatory cells in experimental autoimmune neuritis rats. Exp Neurol. 2009;216(1):75–82.PubMed

144.

Sawicka E et al. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J Immunol. 2003;171(11):6206–14.PubMed

145.

Budde K et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002;13(4):1073–83.PubMed

146.

Schmouder R, Hariry S, David OJ. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol. 68(4):355–62.

Title: Targeting the Molecular and Cellular Interactions of the Bone Marrow Niche in Immunologic Disease
Authors: Jaime M. Brozowski
Matthew J. Billard
Teresa K. Tarrant
Publication date: 01-02-2014
Publisher: Springer US
Published in: Current Allergy and Asthma Reports / Issue 2/2014
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-013-0402-8

At a glance: The STEP trials

Springer Medicine

Targeting the Molecular and Cellular Interactions of the Bone Marrow Niche in Immunologic Disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Indications for Surgery in Refractory Rhinitis

MicroRNA in Chronic Rhinosinusitis and Allergic Rhinitis

Occupational Skin Allergies: Testing and Treatment (The Case of Occupational Allergic Contact Dermatitis)

Preventing Progression of Allergic Rhinitis to Asthma

Genetic Contributors to Otitis Media: Agnostic Discovery Approaches

The Common Cold: Potential for Future Prevention or Cure